AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 6101610
Drug: Psychotropic substances
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychotropic substances (initial standard dose)
Trial: 30644628
Drug: Intranasal 1.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal 1.4 mg naloxone (two doses)
Trial: 30644628
Drug: Intranasal 1.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal 1.4 mg naloxone vs Intramuscular 0.8 mg naloxone
Trial: 19864452
Drug: Saxagliptin (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saxagliptin (2.5 mg) plus TZD
Trial: 19864452
Drug: Saxagliptin (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saxagliptin (5 mg) plus TZD
Trial: 17925592
Drug: Etoricoxib 90
RxNorm normalized name: etoricoxib 90 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etoricoxib 90 mg daily
Trial: 10728939
Drug: alpha‐streptococcal spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: alpha‐streptococcal spray treatment
Trial: 10728939
Drug: placebo spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo spray treatment
Trial: 7536871
Drug: Filgrastim treatment
RxNorm normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Filgrastim treatment for neutrophil recovery
Trial: 31025259
Drug: In ovo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In ovo injection of 1 × 10^9 CFU B. bifidum
Trial: 31025259
Drug: In ovo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In ovo injection of 1 × 10^7 CFU B. bifidum
Trial: 31025259
Drug: In ovo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In ovo injection of 1 × 10^9 CFU B. longum
Trial: 31025259
Drug: In ovo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In ovo injection of 1 × 10^7 CFU B. longum
Trial: 31025259
Drug: Intact (without
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intact (without injection) control group
Trial: 31025259
Drug: In ovo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In ovo injection of bifidobacteria strains
Trial: 28057659
Drug: Lactobacillus reuteri
RxNorm normalized name: Lactobacillus reuteri
DrugBank: Lactobacillus reuteri (DB14224)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacillus reuteri DSM 17938 at a dose of 108 colony-forming units, orally, twice daily during antibiotic treatment
Trial: 28057659
Drug: Placebo, identically
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, identically appearing, orally, twice daily during antibiotic treatment
Trial: 25527751
Drug: High-fat meal
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-fat meal with added protein (61.5% of energy from fat; 51.1 ± 7.9 g of protein; 191.9 ± 9.9 kcal added)
Trial: 21505892
Drug: L-thyroxin (L-T4)
RxNorm normalized name: L-T4
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: L-thyroxin (L-T4) therapy
Trial: 18486783
Drug: Closed treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Closed treatment of nondisplaced, nondislocated fractures (Classes I and VI)
Trial: 16841627
Drug: Pregabalin 400
RxNorm normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pregabalin 400 mg/day
Trial: 10807491
Drug: Venlafaxine 75
RxNorm normalized name: venlafaxine 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venlafaxine 75 mg/day
Trial: 12920975
Drug: Volume Guarantee
RxNorm normalized name: VOLUME EXPANDERS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Volume Guarantee (VG) set at 5 ml/Kg
Trial: 12920975
Drug: Volume Guarantee
RxNorm normalized name: VOLUME EXPANDERS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Volume Guarantee (VG) set at 3 ml/Kg
Trial: 7498858
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment of verapamil retard (240 mg) and hydrochlorothiazide (12.5 mg)
Trial: 7498858
Drug: Monotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monotherapy with verapamil or hydrochlorothiazide
Trial: 2258338
Drug: Pefloxacin (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pefloxacin (400 mg twice daily, orally)
Trial: 2258338
Drug: Ceftazidime (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftazidime (2 g twice daily, iv)
Trial: 6780235
Drug: Proxicromil (18
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proxicromil (18 mg twice per day for the first 3 weeks, then 18 mg four times per day for the next 3 weeks)
Trial: 26809868
Drug: IgG4-guided exclusion
RxNorm normalized name: Humanized IgG4 monoclonal antibody against total complement component 1, subcomponent s
DrugBank: Sutimlimab (DB14996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IgG4-guided exclusion diet (excluding four food types with the highest antibody titers for 4 weeks)
Trial: 26809868
Drug: Sham group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham group (excluding four foods with the lowest antibody titers)
Trial: 23244537
Drug: Flaxseed oil
RxNorm normalized name: Flaxseed Oil
DrugBank: Linseed oil (DB11357)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flaxseed oil (FO) 1 g twice a day for 120 days
Trial: 23244537
Drug: Placebo (mineral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (mineral oil) 1 g twice a day for 120 days
Trial: 17932317
Drug: Rosiglitazone (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosiglitazone (20 mg/kg/d)
Trial: 7599015
Drug: Erythromycin 1.5
RxNorm normalized name: ERYTHROMYCIN 1.5% SOLN,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin 1.5 g
Trial: 29570454
Drug: Repeat/second cesarean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeat/second cesarean with ultrasound-guided intervention (Int-G)
Trial: 29570454
Drug: Second cesarean
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Second cesarean utilizing the usual procedure (CS2-G)
Trial: 28851407
Drug: Second 1000-ml
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Second 1000-ml fluid bolus (standard care)
Trial: 28851407
Drug: Maintenance rate
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance rate fluid only with early commencement of a vasopressor infusion
Trial: 25103924
Drug: Oxytocin (OT)
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxytocin (OT) treatment
Trial: 22021620
Drug: Raltegravir treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raltegravir treatment intensification
Trial: 22021620
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment augmentation (Control)
Trial: 16466830
Drug: Pre- to
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre- to post-weight loss treatment
Trial: 9223393
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg glimepiride daily for 7 days and 10 mg prior to a hyperglycaemic clamp
Trial: 27101556
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg saffron capsule (Crocus sativus L. stigma) twice daily for 12 weeks
Trial: 27101556
Drug: Placebo capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsule twice daily for 12 weeks
Trial: 21801467
Drug: Lingzhi (Ganoderma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lingzhi (Ganoderma lucidum) 1.44 g daily for 12 weeks
Trial: 20842389
Drug: CSII with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CSII with insulin analogues
Trial: 15718180
Drug: Nurse-led intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nurse-led intervention involving patient and family education about heart failure and self-management, and monthly telephone follow-up during 12 months by a primary health care nurse
Trial: 8671790
Drug: Iloprost infusion
RxNorm normalized name: Iloprost
DrugBank: Iloprost (DB01088)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Iloprost infusion (1 ng.kg-1.min-1)
Trial: 8671790
Drug: CsA ingestion
RxNorm normalized name: CsA
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CsA ingestion (3 mg.kg-1)
Trial: 8671790
Drug: Control clearance
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control clearance study without CsA intake or iloprost/placebo infusion
Trial: 1877813
Drug: Intra-arterial infusion
RxNorm normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intra-arterial infusion chemotherapy (IA)
Trial: 1877813
Drug: Systemic chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic chemotherapy (IV)
Trial: 30080229
Drug: Investigational product
RxNorm normalized name: INVESTIGATIONAL AGENTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigational product (Cerbella TM) consisting of an emulsified liquid combination of standardized fish oil, panax ginseng extract, and green tea catechins
Trial: 26950257
Drug: Audio-based cognitive-behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Audio-based cognitive-behavioural therapy (CBT) program
Trial: 7827929
Drug: Ranitidine 100
RxNorm normalized name: ranitidine 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine 100 mg IV twice daily for 4 days, followed by 150 mg orally twice daily for 5 days
Trial: 26667739
Drug: 40 ml/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 ml/day of extra virgin coconut oil
Trial: 23315144
Drug: Tibolone (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tibolone (various doses)
Trial: 21252731
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (cord clamping for 30 seconds)
Trial: 11822785
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg clodronate
Trial: 31891746
Drug: 1000 mg
RxNorm normalized name: bran 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg resveratrol
Trial: 27594544
Drug: Suicide prevention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suicide prevention program (twice a week for 5 weeks)
Trial: 26999890
Drug: Mini-implants (MI)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mini-implants (MI)
Trial: 24459173
Drug: Prehab (exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prehab (exercise and education classes for 60 minutes/day, twice weekly for at least four weeks)
Trial: 18818954
Drug: Ceftibuten 9
RxNorm normalized name: ceftibuten 90 MG in 5 mL Oral Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftibuten 9 mg/kg once daily for 10 days
Trial: 18818954
Drug: TMP‐SMX (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TMP‐SMX (3 mg + 15 mg)/kg twice daily for 10 days
Trial: 15450766
Drug: 20% mannitol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20% mannitol 100 ml IV in 20 min
Trial: 15450766
Drug: Sham infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sham infusion (control)
Trial: 8015241
Drug: Maxaquin 400
RxNorm normalized name: Maxaquin 400mg Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maxaquin 400 mg once a day for 7-14 days
Trial: 8015241
Drug: Ciprofloxacin 500
RxNorm normalized name: ciprofloxacin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin 500 mg twice a day for 7-14 days
Trial: 71970
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg flurbiprofen daily (tablet or liquid suspension)
Trial: 31165663
Drug: Ticagrelor (90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ticagrelor (90 mg BID for 30 days)
Trial: 21382172
Drug: Clopidogrel (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel (600 mg loading dose)
Trial: 31165663
Drug: Clopidogrel (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel (75 mg OD for 30 days)
Trial: 25922838
Drug: Long protocol
RxNorm normalized name: long pepper extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long protocol with combined oral contraceptive (OC) pills
Trial: 25922838
Drug: Short agonist
RxNorm normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short agonist protocol with estradiol priming
Trial: 21748205
Drug: 0.1 mcg/kg/min
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 mcg/kg/min remifentanil infusion (Group R1)
Trial: 21748205
Drug: 0.15 mcg/kg/min
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.15 mcg/kg/min remifentanil infusion (Group R2)
Trial: 19523012
Drug: Diphenhydramine (i.v.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diphenhydramine (i.v. microdose 0.1 mg)
Trial: 19523012
Drug: Diphenhydramine (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diphenhydramine (oral microdose 0.1 mg)
Trial: 19523012
Drug: NBI‐2 (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NBI‐2 (oral microdose 0.1 mg)
Trial: 19523012
Drug: NBI‐1 (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NBI‐1 (oral microdose 0.1 mg)
Trial: 19523012
Drug: NBI‐3 (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NBI‐3 (oral microdose 0.1 mg)
Trial: 19523012
Drug: NBI‐4 (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NBI‐4 (oral microdose 0.1 mg)
Trial: 19523012
Drug: NBI‐4 (i.v.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NBI‐4 (i.v. microdose 0.1 mg)
Trial: 19523012
Drug: NBI‐1 (i.v.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NBI‐1 (i.v. microdose 0.1 mg)
Trial: 19523012
Drug: NBI‐3 (i.v.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NBI‐3 (i.v. microdose 0.1 mg)
Trial: 19523012
Drug: NBI‐2 (i.v.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NBI‐2 (i.v. microdose 0.1 mg)
Trial: 16951472
Drug: PTH and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PTH and raloxifene (combined treatment)
Trial: 12730811
Drug: Water soluble
RxNorm normalized name: WATER SOLUBLE BASE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Water soluble vitamin E (100 mg)
Trial: 2009249
Drug: Antihypertensive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihypertensive treatment (beta-blockers or diuretics)
Trial: 7074750
Drug: Propranolol 80
RxNorm normalized name: propranolol 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol 80 mg every 6 hours
Trial: 7074750
Drug: Metoprolol 50
RxNorm normalized name: metoprolol 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol 50 mg every 6 hours
Trial: 7074750
Drug: Metoprolol 100
RxNorm normalized name: metoprolol 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol 100 mg every 6 hours
Trial: 31732852
Drug: Topical saliva
RxNorm normalized name: Dunaliella salina extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical saliva gel (GC)
Trial: 28844754
Drug: Intramuscular testosterone
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular testosterone enanthate 2 mg/kg (group 2b)
Trial: 25909311
Drug: Transfusion with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transfusion with hemoglobin concentrations maintained above 9.0 g/dL (Group Hb9)
Trial: 25909311
Drug: Withholding transfusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Withholding transfusion unless hemoglobin fell below 7.0 g/dL (Group Hb7)
Trial: 23009800
Drug: Educational slides
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Educational slides about treatment for AUD
Trial: 19919580
Drug: Intrarectal lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intrarectal lidocaine gel (10 ml of 2% lidocaine)
Trial: 19919580
Drug: Caudal block
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caudal block (20 ml 0.1% bupivacaine with 75 microg fentanyl)
Trial: 19042837
Drug: 200 mcg
RxNorm normalized name: CrM 200 MCG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mcg octreotide
Trial: 19042837
Drug: 400 mcg
RxNorm normalized name: Biotin 400 MCG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mcg hyoscine hydrobromide
Trial: 12547870
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care treatment (control)
Trial: 10883420
Drug: Melatonin 2
RxNorm normalized name: melatonin 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin 2 mg intravenously
Trial: 10883420
Drug: Melatonin 2
RxNorm normalized name: melatonin 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin 2 mg orally
Trial: 10883420
Drug: Melatonin 4
RxNorm normalized name: vit B/folic acid/calcium/soy xt/black cohosh xt/melatonin 400 mcg-125 mg-62 mg-40 mg (day)/175 mg-62 mg-1 mg (night) ORAL CAPSULE, SEQUENTIAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin 4 mg orally
Trial: 9535618
Drug: Chronic nitrate
RxNorm normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chronic nitrate therapy
Trial: 22355040
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronic acid (5 mg/100 ml)
Trial: 19116709
Drug: Glycopyrronium bromide
RxNorm normalized name: Glycopyrronium bromide
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Glycopyrronium bromide 0.4 mg every 6 hours for 12 hours
Trial: 19116709
Drug: Scopolamine hydrobromide
RxNorm normalized name: Scopolamine Hydrobromide
DrugBank: Scopolamine (DB00747)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Scopolamine hydrobromide 0.5 mg every 6 hours for 12 hours
Trial: 12821477
Drug: Garenoxacin 100
RxNorm normalized name: Garénoxacine
DrugBank: Garenoxacin (DB06160)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Garenoxacin 100 mg
Trial: 12821477
Drug: Garenoxacin 1200
RxNorm normalized name: Garénoxacine
DrugBank: Garenoxacin (DB06160)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Garenoxacin 1200 mg
Trial: 12821477
Drug: Garenoxacin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Garenoxacin (100 to 400 mg)
Trial: 12821477
Drug: Garenoxacin (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Garenoxacin (400 mg and above)
Trial: 12821477
Drug: Garenoxacin (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Garenoxacin (all doses)
Trial: 8934255
Drug: Doubling the
RxNorm normalized name: THE-630
DrugBank: THE-630 (DB16750)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doubling the amount of LH administered
Trial: 8934255
Drug: Standard amount
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard amount of LH administered
Trial: 1766100
Drug: Midazolam (0.05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (0.05 mg.kg‐1), n = 6
Trial: 1766100
Drug: Midazolam (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (0.1 mg.kg‐1), n = 7
Trial: 6350615
Drug: No postoperative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No postoperative antibiotics
Trial: 29172593
Drug: Internet-delivered cognitive-behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-delivered cognitive-behavioral therapy (iCBT) program for health anxiety (n = 45)
Trial: 6832462
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg indobufen administered orally or by i.v. injection
Trial: 28758526
Drug: Oral Reading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Reading Fluency (ORF) slope
Trial: 18069601
Drug: Antithrombotic therapies
RxNorm normalized name: antithrombin III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antithrombotic therapies for stroke prevention
Trial: 18069601
Drug: Rate control
RxNorm normalized name: tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rate control drugs (old and new)
Trial: 16096180
Drug: 0.03% or
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.03% or 0.1% tacrolimus ointment applied twice daily
Trial: 12030342
Drug: Nicorandil (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicorandil (3 mg/h infusion)
Trial: 12799953
Drug: Butylscopolamine 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Butylscopolamine 20 mg
Trial: 7516295
Drug: Human, recombinant
RxNorm normalized name: Erythropoietin (human, recombinant)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human, recombinant GH (Genotropin, Kabi Pharmacia, Uppsala, Sweden) at a dosage of 0.1 IU/kg body weight per day
Trial: 2680176
Drug: Oral photochemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral photochemotherapy (PUVA) for 4 weeks
Trial: 7305656
Drug: Propranolol hydrochloride
RxNorm normalized name: Propranolol Hydrochloride
DrugBank: Propranolol (DB00571)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propranolol hydrochloride therapy after surgery
Trial: 7305656
Drug: No propranolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No propranolol hydrochloride therapy after surgery
Trial: 22175695
Drug: Water treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Water treatment and hygiene promotion (WT & HP)
Trial: 22175695
Drug: Sanitation improvement
RxNorm normalized name: tetracaine
DrugBank: Tetracaine (DB09085)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sanitation improvement in combination with WT & HP